3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Muscle Invasive Bladder Cancer
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Disease
1
Advanced Solid Malignancies
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
Nivolumab
8
Paclitaxel
6
Sirolimus
5
Bevacizumab
5
temsirolimus
4
Pemetrexed
4
Ipilimumab
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Gemcitabine
3
Erlotinib Hydrochloride
3
olaparib
2
linrodostat
2
apatinib
2
anlotinib
2
abemaciclib
2
Vorinostat
2
Sunitinib
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Everolimus
2
Doxorubicin
2
Dasatinib
2
Chlorogenic Acid
2
Cetuximab
2
6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline
2
vorolanib
1
vistusertib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Advanced Cancer
×
vistusertib
×
Clear all
NCT02193633
2024-09-26
TAX-TORC
Royal Marsden NHS Foundation Trust
Phase 1
Completed
90 enrolled